18:37:38 EST Wed 06 Nov 2024
Enter Symbol
or Name
USA
CA



News for U:JNJ from 2023-11-07 to 2024-11-06 - 96 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-11-04 15:11U:JNJNews ReleaseEmpower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
2024-10-28 15:40U:JNJSEDAR Interim Financial StatementsSEDAR Interim MD & A
2024-10-28 07:30U:JNJNews ReleaseTREMFYA(TM) (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
2024-10-25 08:05U:JNJNews ReleaseNew SPECTREM study findings reveal TREMFYA(TM) (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
2024-10-24 08:00U:JNJNews ReleaseJohnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress
2024-10-15 08:00U:JNJNews ReleaseNipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
2024-10-15 06:25U:JNJNews ReleaseJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
2024-10-15 06:20U:JNJNews ReleaseJohnson & Johnson Reports Q3 2024 Results
2024-10-10 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
2024-10-10 08:00U:JNJNews ReleaseTREMFYA(TM) (guselkumab) demonstrates impressive results across biologic-naive and biologic-refractory patients in Crohn's disease and ulcerative colitis
2024-10-09 08:00U:JNJNews ReleaseJohnson & Johnson Completes Acquisition of V-Wave
2024-10-04 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
2024-10-02 09:00U:JNJNews ReleaseERLEADA(TM) (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
2024-09-30 16:05U:JNJNews ReleaseJohnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO(TM)-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
2024-09-30 08:05U:JNJNews ReleaseJohnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
2024-09-27 16:30U:JNJNews ReleaseCARVYKTI(TM) is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
2024-09-27 13:05U:JNJNews ReleaseDARZALEX(TM) (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
2024-09-27 13:00U:JNJNews ReleaseDARZALEX FASPRO(TM)-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
2024-09-27 08:05U:JNJNews ReleaseNovel combination of TALVEY(TM) (talquetamab-tgvs) and TECVAYLI(TM) (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary
2024-09-27 08:00U:JNJNews ReleaseTALVEY(TM) (talquetamab-tgvs) and DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
2024-09-20 15:43U:JNJNews ReleaseJohnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
2024-09-19 18:54U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
2024-09-16 02:50U:JNJNews ReleaseNeoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
2024-09-15 02:30U:JNJNews ReleaseNew data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
2024-09-14 09:45U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
2024-09-14 03:10U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
2024-09-11 18:22U:JNJNews ReleaseTREMFYA(TM) (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
2024-09-10 17:15U:JNJNews ReleaseDexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT(TM) (amivantamab-vmjw)
2024-09-08 13:47U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
2024-09-05 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results
2024-08-29 08:00U:JNJNews ReleaseJohnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
2024-08-27 08:00U:JNJNews ReleaseJohnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
2024-08-26 08:00U:JNJNews ReleaseJohnson & Johnson's Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
2024-08-20 07:30U:JNJNews ReleaseJohnson & Johnson to Acquire V-Wave
2024-08-20 07:00U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
2024-08-07 17:00U:JNJNews ReleaseGroundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine
2024-08-06 09:00U:JNJNews ReleaseAlzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
2024-07-30 18:45U:JNJSEDAR Interim Financial StatementsSEDAR Interim MD & A
2024-07-30 18:42U:JNJNews ReleaseDARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
2024-07-29 16:00U:JNJNews ReleaseJohnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
2024-07-23 16:00U:JNJNews ReleaseJohnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-07-22 08:00U:JNJNews ReleaseJohnson & Johnson seeks U.S. FDA approval of SPRAVATO(TM) (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
2024-07-17 06:25U:JNJNews ReleaseJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
2024-07-17 06:20U:JNJNews ReleaseJohnson & Johnson reports Q2 2024 results
2024-07-15 08:05U:JNJNews ReleaseNKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
2024-07-11 07:30U:JNJNews ReleaseJohnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
2024-07-02 07:30U:JNJNews ReleaseCARVYKTI(TM) (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
2024-06-28 11:30U:JNJNews ReleaseNipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
2024-06-21 07:30U:JNJNews ReleaseJohnson & Johnson Completes Acquisition of Proteologix, Inc.
2024-06-20 16:30U:JNJNews ReleaseJohnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA(TM) (guselkumab) for the treatment of moderately to severely active Crohn's disease
2024-06-20 08:00U:JNJNews ReleaseTREMFYA(TM) (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
2024-06-17 09:00U:JNJNews ReleaseAcute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
2024-06-17 08:00U:JNJNews ReleaseSubcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
2024-06-15 03:30U:JNJNews ReleaseLate-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study
2024-06-14 08:00U:JNJNews ReleaseTALVEY(TM) (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
2024-06-04 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
2024-05-31 08:45U:JNJNews ReleaseJohnson & Johnson Completes Acquisition of Shockwave Medical
2024-05-30 14:35U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-05-29 17:48U:JNJNews ReleaseSarepta Therapeutics Set to Join S&P MidCap 400
2024-05-28 07:35U:JNJNews ReleaseNumab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
2024-05-28 07:30U:JNJNews ReleaseJohnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
2024-05-16 07:30U:JNJNews ReleaseJohnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
2024-05-08 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-08 15:11U:JNJSEDAR Interim MD & ASEDAR Interim MD & A
2024-05-06 16:05U:JNJNews ReleaseShockwave Medical Reports First Quarter 2024 Financial Results
2024-05-01 06:30U:JNJNews ReleaseJohnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual "Prepackaged" Reorganization
2024-04-22 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC)
2024-04-20 01:28U:JNJSEDAR Annual ReportSEDAR MD & A
2024-04-16 06:25U:JNJNews ReleaseJohnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
2024-04-16 03:20U:JNJNews ReleaseCORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
2024-04-08 18:06U:JNJNews ReleaseJohnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
2024-04-05 23:21U:JNJNews ReleaseCARVYKTI(TM) is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
2024-04-05 06:31U:JNJNews ReleaseJohnson & Johnson to Acquire Shockwave Medical
2024-04-04 18:01U:JNJNews ReleaseJohnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation
2024-04-02 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the BofA Securities Health Care Conference
2024-03-12 09:15U:JNJNews ReleaseArtelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge
2024-03-11 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on First-Quarter Results
2024-03-07 08:33U:JNJNews ReleaseJohnson & Johnson Completes Acquisition of Ambrx
2024-03-01 15:59U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2024-02-20 16:26U:JNJNews ReleaseTECVAYLI ‚ ® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
2024-02-14 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
2024-02-12 16:10U:JNJNews ReleaseJohnson & Johnson to Participate in the Leerink Global Biopharma Conference
2024-02-02 16:10U:JNJNews ReleaseJohnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
2024-01-24 15:42U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-01-23 06:20U:JNJNews ReleaseJohnson & Johnson Reports Q4 and Full-Year 2023 Results
2024-01-08 07:30U:JNJNews ReleaseJohnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
2024-01-02 08:00U:JNJNews ReleaseJohnson & Johnson Announces Quarterly Dividend for First Quarter 2024
2023-12-19 12:05U:JNJSEDAR Interim MD & ASEDAR Interim MD & A
2023-12-12 11:40U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-12-11 16:15U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
2023-12-07 16:15U:JNJNews ReleaseJohnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-07 13:31U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-12-05 07:15U:JNJNews ReleaseJohnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
2023-11-30 16:30U:JNJNews ReleaseJohnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
2023-11-30 08:40U:JNJNews ReleaseJohnson & Johnson MedTech Acquires Laminar, Inc.
2023-11-16 07:30U:JNJNews ReleaseJohnson & Johnson to Host Enterprise Business Review